DE4327732C1 - NO-containing gas mixture for the treatment of pulmonary disorders - Google Patents

NO-containing gas mixture for the treatment of pulmonary disorders

Info

Publication number
DE4327732C1
DE4327732C1 DE19934327732 DE4327732A DE4327732C1 DE 4327732 C1 DE4327732 C1 DE 4327732C1 DE 19934327732 DE19934327732 DE 19934327732 DE 4327732 A DE4327732 A DE 4327732A DE 4327732 C1 DE4327732 C1 DE 4327732C1
Authority
DE
Germany
Prior art keywords
gas mixture
containing gas
treatment
pulmonary disorders
vpm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE19934327732
Other languages
German (de)
Inventor
Christian Krebs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Messer Griesheim GmbH
Original Assignee
Messer Griesheim GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Messer Griesheim GmbH filed Critical Messer Griesheim GmbH
Priority to DE19934327732 priority Critical patent/DE4327732C1/en
Application granted granted Critical
Publication of DE4327732C1 publication Critical patent/DE4327732C1/en
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00Special media to be introduced, removed or treated
    • A61M2202/02Gases
    • A61M2202/0266Nitrogen (N)
    • A61M2202/0275Nitric oxide [NO]

Abstract

Gas mixture for use in NO therapy for spontaneously breathing patients with pulmonary disorders. It is produced by mixing 2-20 vpm NO, preferably 10-16 vpm NO, with nitrogen and medicinal oxygen.

Description

Die Erfindung betrifft ein NO-haltiges Gasgemisch zur Behandlung pulmonaler Erkrankungen nach dem Oberbegriff des Anspruches 1.The invention relates to a gas mixture containing NO Treatment of pulmonary diseases according to the generic term of claim 1.

Die NO-Therapie bei Erwachsenen mit ARDS (adult res­ piratory distress syndrome) ist bekannt. Hierbei werden dem künstlich beatmeten Patienten über die Atemluft ge­ gebenenfalls verhältnismäßig hohe Konzentrationen von NO aus einem mehrere 100 vpm NO enthaltenden Gasbehäl­ ter zugeführt, maximal bis etwa 60 vpm. Das NO wirkt blutdrucksenkend auf den Bluthochdruck im Lungenkreis­ lauf, hat aber keine Wirkung auf den Blutdruck des ge­ samten Kreislaufes. Wegen der hohen Giftigkeit des NO und des zwangsläufig entstehenden NO2, sowie bedingt durch die künstliche Beatmung und der daraus resultie­ renden kleinen kontrollierten NO-Dosiermenge, ist bei der Verabreichung des NO ein großer Überwachungsaufwand erforderlich; vgl. dazu insbesondere R. C. Bone, The New England Journal of Medicine, Vol. 328, No. 6, Feb. 11, 1993, S. 431-432, sowie A. Benzing u. a., Anaesthesist 42 (1993), Springer-Verlag Berlin, S. 175-178.NO therapy in adults with ARDS (adult res piratory distress syndrome) is known. Here, the artificially ventilated patient via the breathing air ge possibly relatively high concentrations of NO from a gas container containing several 100 vpm NO, up to a maximum of about 60 vpm. The NO has a hypotensive effect on the high blood pressure in the pulmonary circulation, but has no effect on the blood pressure of the entire circulation. Because of the high toxicity of the NO and the inevitably arising NO 2 , as well as due to the artificial ventilation and the resulting small controlled NO dosage, a great deal of monitoring is required when administering the NO; see. in particular RC Bone, The New England Journal of Medicine, Vol. 328, No. 6, Feb. 11, 1993, pp. 431-432, and A. Benzing et al., Anaesthesist 42 (1993), Springer-Verlag Berlin, pp. 175-178.

Es ist erstrebenswert, die NO-Therapie auch bei solchen Patienten anzuwenden, die spontan atmen und gegebenen­ falls nicht stationär behandelt werden, damit auch diese Patientengruppe von den Vorteilen der NO-Therapie pro­ fitieren kann.It is worth striving for NO therapy even for those Apply to patients who breathe spontaneously and given if not treated in hospital, so this too Patient group of the benefits of NO therapy pro can fit.

Der Erfindung liegt daher die Aufgabe zugrunde, ein für diesen Zweck geeignetes NO-haltiges Gasgemisch zur Ver­ fügung zu stellen, welches keinen großen Überwachungs­ aufwand erforderlich macht.The invention is therefore based on the object for this purpose suitable NO-containing gas mixture for ver to provide, which is not a major surveillance effort required.

Ausgehend von dem im Oberbegriff des Anspruches 1 be­ rücksichtigten Stand der Technik ist diese Aufgabe er­ findungsgemäß gelöst mit den im kennzeichnenden Teil des Anspruches 1 angegebenen Merkmalen.Based on the be in the preamble of claim 1 considering the state of the art, this task is he solved according to the invention with those in the characterizing part of claim 1 specified features.

Eine vorteilhafte Weiterbildung der Erfindung ist im Unteranspruch angegeben.An advantageous development of the invention is in Subclaim specified.

Bei der praktischen Anwendung des erfindungsgemäßen Gasgemisches wird dieses mit 100%igem medizinischem Sauerstoff so vermischt, daß ein Atemgas aus etwa 30- 50% O2, Rest NO und N2, entsteht. Es ist daher nur sicherzustellen, daß der O2-Gehalt innerhalb der Gren­ zen von ca. 21-50% eingestellt bleibt. Durch die Messung der O2-Konzentration ist der NO-Anteil leicht einstellbar, ohne daß er meßtechnisch erfaßt werden muß. Bei patientennaher Einspeisung des Gemisches bleibt die Bildung des giftigen NO2 äußerst gering. Gut bewährt hat sich in der praktischen Anwendung ein Gemisch mit 10-16 vpm NO in Stickstoff. In the practical application of the gas mixture according to the invention, it is mixed with 100% medical oxygen in such a way that a breathing gas of approximately 30-50% O 2 , the rest NO and N 2 , is formed. It is therefore only necessary to ensure that the O 2 content remains within the limits of approx. 21-50%. By measuring the O 2 concentration, the NO portion can be easily adjusted without having to be measured. When the mixture is fed in close to the patient, the formation of the toxic NO 2 remains extremely low. A mixture with 10-16 vpm NO in nitrogen has proven itself in practical use.

Das erfindungsgemäße NO-haltige Gemisch und der medizi­ nische O2 können auch in zwei kleinen Speichern, z. B. Druckdosen, enthalten sein, die mit fixeingestellten Entnahmearmaturen versehen sind. Eine solche kleine, tragbare Therapieeinheit benötigt keine Steuerung und Kontrolle, so daß sie auch von einem Patienten bei sich zu Hause, beispielsweise bei einem Asthmaanfall, einge­ setzt werden kann.The NO-containing mixture according to the invention and the medicinal African O 2 can also in two small memories, for. B. pressure sockets are included, which are provided with fixed removal taps. Such a small, portable therapy unit does not require control and monitoring, so that it can also be used by a patient at home, for example in the event of an asthma attack.

Claims (2)

1. NO-haltiges Gasgemisch zur Behandlung pulmonaler Erkrankungen bei spontan atmenden Patienten auf der Grundlage eines Atemgases mit ca. 30 bis 50% medizinischem Sauerstoff, dadurch gekennzeichnet, daß das Atemgas mit einer Zusammensetzung von 2 bis 20 vpm NO in Stickstoff erzeugt wird.1. NO-containing gas mixture for the treatment of pulmonary diseases in spontaneously breathing patients on the basis of a breathing gas with about 30 to 50% medical oxygen, characterized in that the breathing gas is generated with a composition of 2 to 20 vpm NO in nitrogen. 2. NO-haltiges Gasgemisch nach Anspruch 1, dadurch gekennzeichnet, daß es durch 10 bis 16 vpm NO in Stickstoff erzeugt wird.2. NO-containing gas mixture according to claim 1, characterized, that it produces NO in nitrogen by 10 to 16 vpm becomes.
DE19934327732 1993-08-18 1993-08-18 NO-containing gas mixture for the treatment of pulmonary disorders Revoked DE4327732C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE19934327732 DE4327732C1 (en) 1993-08-18 1993-08-18 NO-containing gas mixture for the treatment of pulmonary disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19934327732 DE4327732C1 (en) 1993-08-18 1993-08-18 NO-containing gas mixture for the treatment of pulmonary disorders

Publications (1)

Publication Number Publication Date
DE4327732C1 true DE4327732C1 (en) 1994-09-01

Family

ID=6495448

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19934327732 Revoked DE4327732C1 (en) 1993-08-18 1993-08-18 NO-containing gas mixture for the treatment of pulmonary disorders

Country Status (1)

Country Link
DE (1) DE4327732C1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19634530A1 (en) * 1996-08-27 1998-03-05 Messer Griesheim Gmbh Alteration of formation rate or half-life of reactive molecular species
US5904938A (en) * 1995-02-16 1999-05-18 The General Hospital Corporation Treatment of vascular thrombosis and restenosis with inhaled nitric oxide

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3621425A1 (en) * 1986-06-25 1988-01-14 Messer Griesheim Gmbh DEVICE FOR GENERATING A COLD TREATMENT GAS FOR CRYOTHERAPY
DE3938889A1 (en) * 1989-11-24 1991-05-29 Messer Griesheim Gmbh TEMPERATURE TREATMENT CHAMBER FOR CARRYING OUT THERAPEUTIC PROCEDURES
WO1992010228A1 (en) * 1990-12-05 1992-06-25 The General Hospital Corporation Devices for treating pulmonary vasoconstriction and asthma
DE4208521A1 (en) * 1992-03-17 1993-09-30 Heyer Gmbh Carl Inhalation anaesthetics recovery - dries the gas mixture for active carbon adsorption and catalyst to release nitrogen and oxygen into atmosphere and remainder cooled to a fluid for storage or disposal

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3621425A1 (en) * 1986-06-25 1988-01-14 Messer Griesheim Gmbh DEVICE FOR GENERATING A COLD TREATMENT GAS FOR CRYOTHERAPY
DE3938889A1 (en) * 1989-11-24 1991-05-29 Messer Griesheim Gmbh TEMPERATURE TREATMENT CHAMBER FOR CARRYING OUT THERAPEUTIC PROCEDURES
WO1992010228A1 (en) * 1990-12-05 1992-06-25 The General Hospital Corporation Devices for treating pulmonary vasoconstriction and asthma
DE4208521A1 (en) * 1992-03-17 1993-09-30 Heyer Gmbh Carl Inhalation anaesthetics recovery - dries the gas mixture for active carbon adsorption and catalyst to release nitrogen and oxygen into atmosphere and remainder cooled to a fluid for storage or disposal

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BENZING, A., u.a.: Anaesthesist 42(1993), S. 175-178 *
BONE, R.C.: The New England Journal of Medicine, Vol. 328, 6, Feb. 11, 1993, S. 431-432 *
DE-Z: SCHMIDT, H. - BÖHME, E.: Med.Mo.Pharm., 13, 3, 1990, S. 74-81 *
FROSTELL,C.G. et.al.: Anaesthesiology 78, 3, Mai 1993, S. 427-435 *
MANG, H. u.a.: Gefahren und Möglichkeiten der Therapie mit inhaliertem Stickstoffmonoxid, Intensivmed. 29(1992), S. 107-113 *
SCHRÖDER, H.: aaO, 15, 5, 1992, S. 134-139 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5904938A (en) * 1995-02-16 1999-05-18 The General Hospital Corporation Treatment of vascular thrombosis and restenosis with inhaled nitric oxide
US6063407A (en) * 1995-02-16 2000-05-16 The General Hospital Corporation Treatment of vascular thrombosis and restenosis with inhaled nitric oxide
DE19634530A1 (en) * 1996-08-27 1998-03-05 Messer Griesheim Gmbh Alteration of formation rate or half-life of reactive molecular species

Similar Documents

Publication Publication Date Title
DE3533557C2 (en) Measuring device for monitoring the CO¶2¶ content, the oxygen consumption and the respiratory quotient of a patient
DE69724202T2 (en) Method and device for mixing gases
EP0857284B1 (en) Process for providing one or a plurality of rooms with an increased oxygen supply
DE4115124A1 (en) DEODORIZATION AND / OR STERILIZATION DEVICE
DE4327732C1 (en) NO-containing gas mixture for the treatment of pulmonary disorders
DE10210292A1 (en) Artificial respiratory system based on thermal radiation with Co¶2¶ absorbent and canister for use therein
DE4327731C1 (en) NO-containing gas mixture for the treatment of pulmonary disorders
EP0467362A1 (en) Ventilation kit
DE2837281A1 (en) Respirable gas supply for aircraft cabins - by adsorptive removal of nitrogen from compressed air
DE2943365C2 (en)
DE4134384A1 (en) MODIFIED HUMINATES, METHOD FOR THEIR PRODUCTION AND USE
DE2916071A1 (en) METHOD AND DEVICE FOR DERIVING A STUNNING AGENT
Stewart et al. Arterial blood gases before, during, and after nitrous oxide: oxygen administration
DE10261809A1 (en) Regulating oxygen content in closed room involves mixing oxygen-free gas and gas mixture containing oxygen, especially nitrogen/oxygen mixture, with ventilation system at raised internal pressure
Schmid et al. Hochfrequenzbeatmung
DE690972C (en) Device for improving room air
DE19832129C1 (en) Medical gas mixture containing ozone and oxygen for prevention of reperfusion damage in treatment of e.g. ulcers, burns, infections and oedemas
DE19634530A1 (en) Alteration of formation rate or half-life of reactive molecular species
Lercher Glyoxalase 1 activity in atherosclerotic lesions: is there an association with serum haemoglobin A1c?
DE4243679A1 (en) Multi gas mixer
Fillmore et al. Curare sensitivity in myasthenia gravis
DE8104474U1 (en) DEVICE FOR PRODUCING AN AEROSOL BY MEANS OF ULTRASOUND
Merkle et al. Influence of Factor XIII on Wound Healing Under Normal and Pathophysiologic Conditions
CH226793A (en) Device for performing anesthesia.
Kowald High-Frequency Oscillatory Ventilation (HFOV)

Legal Events

Date Code Title Description
8100 Publication of the examined application without publication of unexamined application
D1 Grant (no unexamined application published) patent law 81
8363 Opposition against the patent
8331 Complete revocation